Compare FRPT & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRPT | ACAD |
|---|---|---|
| Founded | 2004 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.9B |
| IPO Year | 2014 | 2000 |
| Metric | FRPT | ACAD |
|---|---|---|
| Price | $60.35 | $21.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 22 |
| Target Price | ★ $80.29 | $30.45 |
| AVG Volume (30 Days) | 1.7M | ★ 1.7M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 183.87 | 69.12 |
| EPS | ★ 2.64 | 2.30 |
| Revenue | ★ $1,102,015,000.00 | $726,437,000.00 |
| Revenue This Year | $11.34 | $18.90 |
| Revenue Next Year | $9.21 | $11.62 |
| P/E Ratio | $22.20 | ★ $9.11 |
| Revenue Growth | 13.01 | ★ 40.45 |
| 52 Week Low | $46.76 | $14.08 |
| 52 Week High | $89.80 | $28.35 |
| Indicator | FRPT | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 28.40 | 48.65 |
| Support Level | $48.93 | $20.45 |
| Resistance Level | $66.07 | $22.75 |
| Average True Range (ATR) | 4.41 | 0.76 |
| MACD | -2.48 | 0.09 |
| Stochastic Oscillator | 25.35 | 71.57 |
Freshpet produces and sells premium fresh pet food through its company-owned refrigerators placed in grocery, mass and club, pet specialty, and natural stores. Freshpet primarily targets dogs (96% of 2024 sales), with cats and treats comprising the rest of its sales. Geographically, the company's home US market, where all its food is produced, accounts for about 98% of sales, with exports to Canada, the United Kingdom, and other European countries accounting for the remaining balance.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.